Mega Lifesciences PCL manufactures, markets and distributes nutritional and herbal supplement, OTC and ethical drugs. The Company produces products that range from treating internal issues to overall general health.

Management Discussion And Analysis Quarter 3 Ending 30 Sep 2024

Financial Performance Quarter 3 (F45) (Reviewed)

Financial Statement Quarter 3/2024 (Reviewed)

Right Of Shareholders To Propose Agenda And Nominees To Be Elected As Company'S Directors, And Submit Questions In Advance For The 2025 Annual General Meeting Of Shareholders

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mega Lifesciences (MEGA TB)

Management Discussion And Analysis Quarter 3 Ending 30 Sep 2024

Financial Performance Quarter 3 (F45) (Reviewed)

Financial Statement Quarter 3/2024 (Reviewed)

Right Of Shareholders To Propose Agenda And Nominees To Be Elected As Company'S Directors, And Submit Questions In Advance For The 2025 Annual General Meeting Of Shareholders

Management Discussion And Analysis Quarter 2 Ending 30 Jun 2024

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)